Earnings call transcript: Botanix trims costs as Q1 2027 revenue stalls

Botanix Pharmaceuticals reported flat Q1 2027 revenue at $10.1 million, despite a 32% increase in prescriptions shipped to 35,130. The company's shares fell 3.85% to $0.013, nearing the bottom of its 52-week range. Gross-to-net yield dropped to 21%, attributed to weaker prior authorization submission volumes. Management cut headcount by about 60% and operating expenses by roughly 50%.

Botanix aims for a 30% to 40% gross-to-net yield and lower cash burn in future quarters. The company's latest quarter showcased a transition from a development-stage to a commercial profile, but highlighted challenges in converting demand to revenue.